Currently out of the existing stock ratings of Gary Nachman, 204 are a BUY (71.08%), 82 are a HOLD (28.57%), 1 are a SELL (0.35%).

Gary Nachman

Work Performance Price Targets & Ratings Chart

Analyst Gary Nachman, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 47.51% that have a potential upside of 55.15% achieved within 412 days.

Gary Nachman’s has documented 584 price targets and ratings displayed on 42 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SRRK, Scholar Rock Holding Corp at 14-Sep-2026.

Wall Street Analyst Gary Nachman

Analyst best performing recommendations are on EVLO (EVELO BIOSCIENCES).
The best stock recommendation documented was for PCRX (PACIRA PHARMACEUTICALS) at 2/14/2018. The price target of $32 was fulfilled within 2 days with a profit of $4.1 (11.36%) receiving and performance score of 56.79.

Average potential price target upside

of $54.66 (40.22%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $41.46 (595.63%) on SRRK (SCHOLAR ROCK HOLDING CORP).
of $40.78 (29.9%) on ABBV (ABBVIE).

AMPH Amphastar P APTX Aptinyx AQST Aquestive Therapeutics BHC Bausch Health Companies ENDP Endo International PLC FLXN Flexion Therapeutics HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC LCI Lannett Company MNK Mallinckrodt plc MYL Viatris NEOS Neos Therapeutics OPTN OptiNose PCRX Pacira Pharmaceuticals SAGE Sage Therapeutic ABBV AbbVie PHAT Phathom Pharmaceuticals RIGL Rigel Pharmaceuticals PYPD PolyPid VTRS Viatris SRRK Scholar Rock Holding Corp TEVA Teva Pharma Industries Ltd ADR MORF Morphic ALNY Alnylam Pharmaceuticals ABCL Abcellera Biologics EVLO Evelo Biosciences SDGR Schrodinger SLGL Sol Gel Technologies Ltd AMGN Amgen IONS Ionis Pharmaceuticals TRVI Trevi Therapeutics VERU Veru BLCO Bausch + Lomb Corp AP Ampco-Pittsburgh INMB INmune Bio LENZ LENZ Therapeutics SA Seabridge Gold ACHV Achieve Life Sciences ADMA ADMA Biologics AMRX Amneal Pharmaceuticals, Common Stock ANIP ANI Pharmaceuticals ETON Eton Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Glen Santangelo (BARCLAYS)

Hold Since 08-Apr-2026

$23

$-3.13 (-11.98%)

$20

1 months 14 days ago
(18-Aug-2026)

5/8 (62.5%)

$1.66 (7.78%)

Please subscribe to see extended stock data

Benjamin Burnett (WELLS FARGO)

Hold Since 07-Aug-2026

$20

$-6.13 (-23.46%)

$19

1 months 25 days ago
(07-Aug-2026)

2/3 (66.67%)

$-0.78 (-3.75%)

Please subscribe to see extended stock data

David Amsellem (PIPER SANDLER)

Hold Since 21-Mar-2025

$20

$-6.13 (-23.46%)

$21

1 months 25 days ago
(07-Aug-2026)

13/20 (65%)

$-0.78 (-3.75%)

263

Please subscribe to see extended stock data

Jason Gerberry (BAML)

Hold Since 26-Aug-2025

$20

$-6.13 (-23.46%)

3 months 3 days ago
(29-Jun-2026)

2/4 (50%)

$-0.71 (-3.43%)

Please subscribe to see extended stock data

Cerena Chen (WELLS FARGO)

Buy Since 22-Nov-2024

$19

$-2.78 (-12.76%)

$35

4 months 18 days ago
(14-May-2026)

1/3 (33.33%)

$1.7 (9.83%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Gary Nachman most bullish on?

Potential upside of $52.05 has been obtained for JAZZ (JAZZ PHARMACEUTICALS PLC)

Which stock is Gary Nachman most reserved on?

Potential downside of $5.46 has been obtained for ACHV (ACHIEVE LIFE SCIENCES)

What Year was the first public recommendation made by Gary Nachman?

On 2013